Trevena Inc (NASDAQ:TRVN)

2.60
Delayed Data
As of Oct 21
 -0.18 / -6.47%
Today’s Change
0.46
Today|||52-Week Range
3.68
+209.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$436.4M

Company Description

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Contact Information

Trevena, Inc.
955 Chesterbrook Boulevard
Chesterbrook Pennsylvania 19087
P:(610) 354-8840
Investor Relations:

Employees

Shareholders

Mutual fund holders5.93%
Other institutional4.42%
Individual stakeholders13.87%

Top Executives

Carrie L. BourdowPresident, Chief Executive Officer & Director
Barry ShinChief Financial Officer & Senior Vice President
Michael S. KramerVP-Scientific Operations & Alliance Management
Linda C. WaseVP-Clinical Operations & Medical Affairs
Mark A. DemitrackChief Medical Officer & Senior Vice President